InspireMD Inc
XBER:II2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (21.1), the stock would be worth €-2 504.83 (42 969% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0 | €5.84 |
0%
|
| Industry Average | 21.1 | €-2 504.83 |
-42 969%
|
| Country Average | 16 | €-1 900.89 |
-32 633%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| IL |
|
InspireMD Inc
XBER:II2
|
55.7m EUR | -0 | -1.1 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
60.7B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.7T JPY | 33.6 | 38.6 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.2B CHF | 28 | 37.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
94.7B DKK | 14.9 | 23.5 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.6B USD | 19.9 | 33.2 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.4B GBP | 17.6 | 32.1 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 54.4 | -15.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
890.2B JPY | 32.4 | 50.3 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
7.9T KRW | -76.3 | -36 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.3B USD | 18 | 22.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10.7 |
| Median | 16 |
| 70th Percentile | 23.8 |
| Max | 877.3 |
Other Multiples
InspireMD Inc
Glance View
InspireMD, Inc. operates as a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
